Spending 24k a month on R&D and 354k a month on Kenny and friends pay is not unlocking any value. Try and find any Real Biotech with no products or clinical trial activity that spends more on executive pay than R&D never mind 15 times more on executive pay than R&D.

206,000,000 shares sold since 4/1/19. 1.3 million raised. 75k spent on R&D the rest on paying Kenny and friends. Cash on hand as of last 10q already gone and PMCB has a negative balance sheet. Tens or Hundreds of millions of shares probably already sold since last 10q for .005 or less just to fund Kenny and friends. No partnerships, foundations or any other means to pay for Ind never mind the $Millions in start up cost for trial sites and $Millions to conduct a trial. The good news is PMCB never plans on conducting trials because they a simply a PR's issuing stock selling penny stock scam. Financial reports tell the tale all you have to do is read them. IMHO

PMCB is in business to sell shares and pay Management and Friends. 75k spent on R&D over a 3 month period and over a Million spent on Kenny and friends. Selling shares to friends at 75%+ discounts only to fund payroll.


.005 A SHARE
From August 1, 2019 through August 8, 2019, the Company sold 70,000,000 shares of common stock as a Block Trade using the S-3. The issuance of these shares resulted in gross proceeds to the Company of approximately $350,000.


.00695 A SHARE
From May 1, 2019 through August 12, 2019, the Company sold 136,666,667 shares of common stock using the Second S-3 structured as a Block Trade. The issuance of the seshares resulted in gross proceeds to the Company of approximately $950,000.

If I had a share of PMCB for ever time a PMCB Investor proclaimed "Exciting times ahead" over the past years i would have a boat load of shares. They still wouldn't be worth anything but i would have a boat load.

Foolish to believe any of the people contribute anything to PMCB. They all go to work at their real job every day and spend ZERO time on PMCB. The two Austrianova guys can't even produce their own product from 20 years ago. Who showed up for the Shareholder meeting? Any of the BOD? PMCB's PI? Their chief Medical officer? Any of their "consultants" ? Their COO? Any of them ever bought PMCB shares with their own money? Overlooking the financials of where this company spends money and how much money they actually have on hand and instead creating a "fairy tale" of what some want to believe is not logical.

Shares left? PMCB sells them to this investor continuously so there will always be shares they are flipping.

rooting against this company?
No its called calling out a company for what they are. A penny stock PR issuing share selling scam. 7 years of clinical trials this year and their financials show almost ZERO spent on R&D. Almost every penny raised by selling .005 shares goes to paying A old Lawyer his CFO pal from their previous Penny Stock Scam and Kenny's Buds.

Shady Kenny's 7 year game of Kick the Can continues. The association with SMMG also continues which only solidifies the fact that PMCB is a Scam just like every other Penny Stock SMMG has been associated with. More money spent every qtr paying for stock promotion than R&D and two penny stock Scam Artists running a fake Biotech is all PMCB has ever been.

Cheaply based on what? PMCB sells shares by the tens of millions at .005. There isn't a real company out there that would buyout PMCB even at .005. No Cash on hand, no pre-clinical or clinical data ever released, no research facility, possibly expired patents, no regulatory personnel, no scientific personnel. .005 X 1.4 billion shares. No not worth $7 million to anyone never mind the $50 million market cap it is today.

Shady Kenny's 7 year game of Kick the Can continues. The association with SMMG also continues which only solidifies the fact that PMCB is a Scam just like every other Penny Stock SMMG has been associated with. More money spent every qtr paying for stock promotion than R&D and two penny stock Scam Artists running a fake Biotech is all PMCB has ever been.

When is the last time a Real Biotech partnered with a 3 cent company that has no pre-clinical or clinical data, no research facility, no regulatory personnel, unknown patent status and spends less money a month on R&D than it pays its Lawyer CEO? NEVER Going to Happen but Shady has used his Shady speak by not answering because "if" he was speaking to someone he couldn't talk about it. LOL What a complete piece of garbage he and PMCB is. But don't worry Shady has funding at .005 lined up so he and his buddy Carlos can get PAID.

Research and development costs $72,330. Total operating expense 1,134,075. Ya LOTS and LOTS of R&D going on. LOL

Friday after market close CC. Nothing good is EVER announced.

WOW Getting close to the big.............. Nothing. But enjoy Shady's pre-recorded fluff. I am sure there will be wild guessing and decoding of every word said and unsaid all weekend. Just the kind of investor chaos that PMCB likes. Make them feel like something is going on even though logic proves otherwise.

Material developments are NOT Material Events.

Prediction! There will be more questions and baseless speculation after the call then there is right now. No real answers No timelines That's how Penny Stock Scams like PMCB work. Maybe Shady will spend the first 45 minutes detailing exactly how CIAB works again for the 500th time.

If Shady Kenny is releasing "Good News" on a Friday Afternoon after market close then he truly is a Moron.

Absolutely. LOL. For Companies trying to sell .005 shares. For Longs not so much.

Also deserves a re-post.

Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

I believe that is for New Drug Applications and not Investigation Drug Applications but that's irreverent because PMCB is not a real Biotech and none of the Nonsense posted about foundations and partners and buyouts or clinical trials will ever happen. All one has to do is read their 10q's to discover the only thing going on here is sell shares at .005 and pay management and friends. 10q reports are not make believe.

$2.5-$3 Million at .005 a share. LOL 500,000,000 shares and that only covers existing costs. No Ind money No Trial money. PMCB plans to do nothing but pay Management for the next 12-18 months.

Chicago is in the past and there is no future in the past.

News must be leaking because 1/10th of 1 percent of shares traded. LOL Rinse repeat! Keep trying to fit that huge square peg into the tiny PMCB hole.

When you are trying to dump tens of millions of share you bought for .005 in a company that does nothing it cost $$. This is just one article you can only imagine the hundreds of penny stock email alerts that have gone out. I believe what you are seeing is an end of PMCB as the Hype just doesn't work anymore. Soon this .005 buyer won't have the ability to sell and that will be the end.

Article was released on this site on 9/16/19. Extended again and again because PMCB is in a constant state of Stock Promotion. When you do nothing and you have 1.3 BILLION shares O/S stock promotion is all there is.

https://ih.advfn.com/stock-market/USOTC/pharmacyte-biotech-inc-PMCB/stock-news/80737056/top-4-penny-stocks-to-watch-this-week

There is a Stock Promotional Owner out there with Millions of Shares just trying to create a demand so the 700k opening was a nice try but there is no appetite anymore for PMCB stock. And a CC on a Friday after market close isn't going to be good news.

Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

The SEC requires public companies to file quarterly financial reports so that shareholders and potential shareholders can see what companies actually do. What they receive in revenue, what they spend and where they spend it, how many shares they issue and what they received for those shares and disclose any business dealings and many other things. It is LOL hysterical that some can completely disregard everything in PMCB's financial report and instead proclaim everything that is not in there. PMCB is a financial disaster with a negative balance sheet selling hundreds of millions of shares at 70% discounts to a stock promotional companies and using that money almost exclusively to pay two former penny stock scammers from Chinatel Corp. A pretend Biotech proven by the fact that they spend almost ZERO $ on R&D. Never once in 8 years publishing any clinical or pre-clinical data. No research facility or regulatory personnel. A Sham using horrible diseases as a means to enrich themselves.

Fool PMCB Investors once shame on Kenny. Fool PMCB investors hundreds of times .......

Anyone here should read the past 200 Pr's to see this company has never accomplished anything but issuing Pr's. Then read the companies latest 10q to see that 95% of all the money this company raises ever quarter selling shares at half a penny is spent on paying management salaries. A company that spends practically no money on R&D and has no cash on hand to even file an Ind is not a real biotech its a penny stock scam company.

A Scheduled Friday CC. What company ever has scheduled a Friday CC at 4pm over a week in advance to report Good News? A "Biotech" that spends 5.5k a week on R&D has no Good News to present only fluff and diversion. Shady will tell everyone how its so complicated and Blah Blah all of the great things they are working on and the Long Long Long Longs will eat up every word. PMCB is a Scam and their Financial Reports Prove It.

MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019.

Indirectly he pays for it.PMCB Selling hundreds of millions of shares to Complete Investment And Management LLC. for .005 who in turn pay Midam Ventures LLC, who own www.StockPrice.com to promote it on their site and the countless other scam penny stock sites. Its a tangled web Shady weaves but he is an old pro at it.

Shady sells shares at .005 to Complete Investment And Management LLC.and gets paid.

Complete Investment And Management LLC. pays Midam Ventures LLC, to promote the shares and they get paid.

Complete Investment And Management LLC. sells the shares at market price to investors and they get paid.

Guess who never gets paid.

Promotional Article.

Penny Stocks To Watch #1: PharmaCyte Biotech (PMCB)
There has been no lack of attention on biotech penny stocks this year. At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes.
The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box® is the platform that the company uses to develop its therapy delivery methods. For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 12, PharmaCyte saw more than 4 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

Second, the company has been ramping up for a much-anticipated shareholder update call on September 20. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.

This (Below) is what type of company PMCB is. They sell hundreds of millions of shares at .005 to a company to pay themselves then that company promotes the stock to sell to naive investors. Its called a penny stock scam.


MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

At the current rate of spending and the purchase price of shares sold in block trades PMCB will have to sell 242,000,000 shares a quarter just to meet expenses. That is reality. All while as a "Biotech" they spend less a month on R&D (24k) than they pay their CEO (56k) and CFO (39K) and now have a negative balance sheet. No Money , Not developing anything as proven by recent 10q.

Once again the financials don't lie like Shady. A Biotech that claims to be working 24/7/365 and yet spends only 24k a month on R&D is not working on anything. 24k is less than Shady makes a month.

PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.

PMCB is spending 24k a month on R&D so it is obvious they are working on Nothing. But I am sure Shady Kenny will use Kenny Speak to make it appear there is "So Much" going on.

The same Board that No Shows a Shareholder Meeting. Sure Keep buying Kaboom. LMFAO

Negative balance sheet and selling shares at .005. 75k spent on R&D or
25k a month and this is the company that is going to change the way solid tumors are treated. What an absolute JOKE.


From August 1, 2019 through August 8, 2019, the Company sold 70,000,000 shares of common stock as a Block Trade using the S-3. The issuance of these shares resulted in gross proceeds to the Company of approximately $350,000. Pursuant to the Engagement Agreement, the Company paid Aeon a fee of 7%, $24,500, and provided warrant coverage of 5% of the number of shares of commons stock sold in the Block Trade with a five-year term for 3,500,000 warrant shares.

As of July 31, 2019, our cash totaled approximately $328,000, compared to approximately $1.8 million at July 31, 2018. Working capital was approximately a negative $130,000 at July 31, 2019